0001144204-16-089285.txt : 20160321 0001144204-16-089285.hdr.sgml : 20160321 20160321172951 ACCESSION NUMBER: 0001144204-16-089285 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20160321 DATE AS OF CHANGE: 20160321 EFFECTIVENESS DATE: 20160321 FILER: COMPANY DATA: COMPANY CONFORMED NAME: EYEGATE PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001372514 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-259702 FILM NUMBER: 161519474 BUSINESS ADDRESS: STREET 1: 271 WAVERLEY OAKS ROAD STREET 2: SUITE 108 CITY: WALTHAM STATE: MA ZIP: 02452 BUSINESS PHONE: 781-788-9043 MAIL ADDRESS: STREET 1: 271 WAVERLEY OAKS ROAD STREET 2: SUITE 108 CITY: WALTHAM STATE: MA ZIP: 02452 D 1 primary_doc.xml X0707 D LIVE 0001372514 EYEGATE PHARMACEUTICALS INC 271 WAVERLEY OAKS ROAD SUITE 108 WALTHAM MA MASSACHUSETTS 02452 (781) 788-8869 DELAWARE None None Corporation true Stephen From c/o EyeGate Pharmaceuticals, Inc. 271 Waverley Oaks Road, Suite 108 Waltham MA MASSACHUSETTS 02452 Executive Officer Director Paul Chaney c/o EyeGate Pharmaceuticals, Inc. 271 Waverley Oaks Road, Suite 108 Waltham MA MASSACHUSETTS 02452 Director Morton F. Goldberg c/o EyeGate Pharmaceuticals, Inc. 271 Waverley Oaks Road, Suite 108 Waltham MA MASSACHUSETTS 02452 Director Praveen Tyle c/o EyeGate Pharmaceuticals, Inc. 271 Waverley Oaks Road, Suite 108 Waltham MA MASSACHUSETTS 02452 Director Thomas Balland c/o EyeGate Pharmaceuticals, Inc. 271 Waverley Oaks Road, Suite 108 Waltham MA MASSACHUSETTS 02452 Director Thomas E. Hancock c/o EyeGate Pharmaceuticals, Inc. 271 Waverley Oaks Road, Suite 108 Waltham MA MASSACHUSETTS 02452 Director Bernard Malfroy-Camine c/o EyeGate Pharmaceuticals, Inc. 271 Waverley Oaks Road, Suite 108 Waltham MA MASSACHUSETTS 02452 Director Mounia Chaoui c/o EyeGate Pharmaceuticals, Inc. 271 Waverley Oaks Road, Suite 108 Waltham MA MASSACHUSETTS 02452 Director Pharmaceuticals Decline to Disclose 06b false 2016-03-07 false true true On March 7, 2016, the Company entered into a Stock Purchase Agreement. The Company acquired 100% of the outstanding equity interests of Jade Therapeutics, Inc. ("Jade") and Jade became a wholly-owned subsidiary of the Company. 0 2618797 2618797 0 Market value of the issued shares based on closing price on the date of issuance true 27 32 0 0 0 false EYEGATE PHARMACEUTICALS INC /s/ Stephen From Stephen From President & Chief Executive Officer 2016-03-21